Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD)

Helena A. Yu(Memorial Sloan Kettering Cancer Center), Jonathan W. Riess(University of California Davis Medical Center), Sarah B. Goldberg(Yale University), Jonathan W. Goldman(University of California, Los Angeles), P. Szekeres(AstraZeneca (Netherlands)), Paul D. Smith(Epworth Hospital), Gail Doughton(AstraZeneca (United Kingdom)), Silvija Kraljevic(AstraZeneca (United Kingdom)), Ilhem Mensi(AstraZeneca (United Kingdom)), Phil Jewsbury(AstraZeneca (United Kingdom)), Adrianus J. de Langen(The Netherlands Cancer Institute), Julie Maidment(AstraZeneca (United Kingdom)), Juliann Chmielecki(Memorial Sloan Kettering Cancer Center), Byoung Chul Cho(Yonsei University), Zofia Piotrowska(Global Cancer Institute), Isamu Okamoto(Kyushu University Hospital), Xiaocheng Li-Sucholeiki(AstraZeneca (United States)), Xiuning Le(The University of Texas MD Anderson Cancer Center), Helen Ambrose(AstraZeneca (United Kingdom)), Gargi Patel(AstraZeneca (United Kingdom))
Clinical Lung Cancer
June 25, 2021
10.1016/j.cllc.2021.06.006
Cited by 73

Related Papers

Comprehensive molecular profiling of lung adenocarcinoma
|Nature|2014|5.9k
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2019|3.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M
|Nature Medicine|2015|1.5k
Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2022|1.4k